Ohr Pharmaceutical Inc (OHRP)

2.71
0.10 3.74
NASDAQ : Health Care
Prev Close 2.81
Open 2.81
Day Low/High 2.68 / 2.83
52 Wk Low/High 2.42 / 6.56
Volume 142.14K
Avg Volume 109.40K
Exchange NASDAQ
Shares Outstanding 32.10M
Market Cap 90.21M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ohr Pharmaceutical Reports Second Quarter 2016 Financial And Business Results

Ohr Pharmaceutical Reports Second Quarter 2016 Financial And Business Results

Conference Call Today at 5:00pm Eastern Time

Ohr Pharma (OHRP) Stock Surges After Launching Phase 3 Trial

Ohr Pharma (OHRP) Stock Surges After Launching Phase 3 Trial

Ohr Pharma (OHRP) stock is advancing in early afternoon trading on Tuesday after the company launched a Phase 3 study for its lead drug candidate.

Ohr Pharmaceutical, Inc. Announces SPA Agreement With US FDA And Initiation Of Phase III Wet AMD Clinical Program

Ohr Pharmaceutical, Inc. Announces SPA Agreement With US FDA And Initiation Of Phase III Wet AMD Clinical Program

First of Two Planned Phase III Trials Initiated to Evaluate Squalamine (OHR-102) Combination Therapy for the Treatment of Wet AMD

8 Stocks Under $10 Making Big Moves Higher

8 Stocks Under $10 Making Big Moves Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Ohr Pharmaceutical Announces Submission Of A Special Protocol Assessment And Upcoming Presentation On OHR-102 At American Academy Of Ophthalmology

Ohr Pharmaceutical Announces Submission Of A Special Protocol Assessment And Upcoming Presentation On OHR-102 At American Academy Of Ophthalmology

Additional Results From Phase II IMPACT Study to be Featured at Podium Presentation at AAO on Friday November 13

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks under $10 are within range of triggering breakout trades.

Ohr Pharmaceutical Reports Fiscal Third Quarter 2015 Financial And Business Results

Ohr Pharmaceutical Reports Fiscal Third Quarter 2015 Financial And Business Results

Conference Call Today, Thursday, August 6 at 5pm Eastern

Ohr Pharmaceutical Promotes Jason S. Slakter, MD To Chief Executive Officer

Ohr Pharmaceutical Promotes Jason S. Slakter, MD To Chief Executive Officer

Dr. Taraporewala Appointed Chief Technology Officer

3 Stocks Under $10 Making Big Moves

3 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Ohr Pharmaceutical (OHRP) Stock Climbs on Positive Retinal Vein Occlusion Phase II Study Results

Ohr Pharmaceutical (OHRP) Stock Climbs on Positive Retinal Vein Occlusion Phase II Study Results

Ohr Pharmaceutical (OHRP) shares are up over 30% today after the company announced positive results from the phase II study of its retinal vein occlusion treatment candidate OHR-102.

Ohr Pharmaceutical Announces Positive Results Of A Phase II Clinical Study For OHR-102 In Retinal Vein Occlusion

Ohr Pharmaceutical Announces Positive Results Of A Phase II Clinical Study For OHR-102 In Retinal Vein Occlusion

OHR-102 Combination Therapy Enhances Visual Recovery in Macular Edema Secondary to Retinal Vein Occlusion

OHRP: Insiders Vs. Shorts

OHRP: Insiders Vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 05/15/2015 settlement date, and Ohr Pharmaceutical, Inc. is one of the most shorted stocks of the Russell 3000, based on 10.41 "days to cover" versus the median component at 5.60.

5 Stocks Under $10 Triggering Breakout Trades

5 Stocks Under $10 Triggering Breakout Trades

Keep these under-$10 stocks on your breakout trading radar.

Ohr Pharmaceutical Reports Fiscal Second Quarter 2015 Financial And Business Results

Ohr Pharmaceutical Reports Fiscal Second Quarter 2015 Financial And Business Results

Conference Call Today, Monday, May 11 at 5pm Eastern